Currently, pathogenic variants in more than 500 different genes are known to cause various
movement disorders. The increasing accessibility and reducing cost of genetic testing has …

Glucocerebrosidase (GBA1) variants constitute numerically the most common known
genetic risk factor for Parkinson's disease (PD) and are distributed worldwide. Access to …

Background Heterozygous variants in the glucocerebrosidase (GBA1) gene are the most
common genetic risk factor for Parkinson's Disease (PD). GBA1-PD patients exhibit earlier …

Parkinson's disease (PD) is the second-most common neurodegenerative disease, affecting
1% of people aged over 60. Currently, there is only symptomatic relief for PD patients, with …

Profiling circulating lipids and metabolites in Parkinson's disease (PD) patients could be
useful not only to highlight new pathways affected in PD condition but also to identify …

Device aided therapies (DAT) comprising the intrajejunal administration of
levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel …

Background The availability of deep brain stimulation (DBS), a highly efficacious treatment
for several movement disorders, remains low in developing countries, with scarce data …

Severe non-infectious or non-haemorrhagic brain edema surrounding the electrode
represents a rare complication of subthalamic nucleus deep brain stimulation (STN-DBS) …

In this review, different aspects of the use of clinical neurophysiology techniques for the
treatment of movement disorders are addressed. First of all, these techniques can be used to …

Background Subjects carrying mutations in the GBA gene, whether in one or two alleles
pose a risk to develop Parkinson's disease (PD). This type of GBA-related PD has usually a …